Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:APHA NYSE:BHC NYSE:PBH NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHAAphriaC$0.00C$3.93▼C$40.93C$5.24BN/A6.16 million shs9.61 million shsBHCBausch Health Cos$4.43-0.6%$5.00$4.33▼$8.69$1.66B0.422.60 million shs1.23 million shsPBHPrestige Consumer Healthcare$49.67+1.5%$47.94$42.62▼$77.03$2.32B0.35571,023 shs350,482 shsSLSSELLAS Life Sciences Group$11.32-8.3%$10.36$1.39▼$15.88$2.43B2.4210.68 million shs6.71 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPHAAphria0.00%0.00%0.00%0.00%0.00%BHCBausch Health Cos-0.67%-8.86%-11.23%-21.33%-33.41%PBHPrestige Consumer Healthcare+1.64%-0.50%+4.93%-15.77%-35.22%SLSSELLAS Life Sciences Group-8.27%-14.18%+23.45%+153.81%+515.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHAAphriaC$0.00C$3.93▼C$40.93C$5.24BN/A6.16 million shs9.61 million shsBHCBausch Health Cos$4.43-0.6%$5.00$4.33▼$8.69$1.66B0.422.60 million shs1.23 million shsPBHPrestige Consumer Healthcare$49.67+1.5%$47.94$42.62▼$77.03$2.32B0.35571,023 shs350,482 shsSLSSELLAS Life Sciences Group$11.32-8.3%$10.36$1.39▼$15.88$2.43B2.4210.68 million shs6.71 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPHAAphria0.00%0.00%0.00%0.00%0.00%BHCBausch Health Cos-0.67%-8.86%-11.23%-21.33%-33.41%PBHPrestige Consumer Healthcare+1.64%-0.50%+4.93%-15.77%-35.22%SLSSELLAS Life Sciences Group-8.27%-14.18%+23.45%+153.81%+515.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPHAAphria 0.00N/AN/AN/ABHCBausch Health Cos 1.83Reduce$8.0080.79% UpsidePBHPrestige Consumer Healthcare 2.00Hold$70.7542.43% UpsideSLSSELLAS Life Sciences Group 2.33Hold$10.00-11.66% DownsideCurrent Analyst Ratings BreakdownLatest SLS, APHA, PBH, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2026BHCBausch Health Cos Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/17/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026SLSSELLAS Life Sciences Group Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/25/2026PBHPrestige Consumer Healthcare Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/18/2026PBHPrestige Consumer Healthcare Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/15/2026PBHPrestige Consumer Healthcare Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$86.00 ➝ $72.005/14/2026PBHPrestige Consumer Healthcare Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/14/2026PBHPrestige Consumer Healthcare OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/7/2026PBHPrestige Consumer Healthcare OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$77.00 ➝ $65.005/4/2026BHCBausch Health Cos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/27/2026BHCBausch Health Cos Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$10.00 ➝ $9.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPHAAphriaC$611.06M0.00N/A22.40C$4.76 per share0.00BHCBausch Health Cos$10.53B0.16$7.25 per share0.61$1.02 per share4.34PBHPrestige Consumer Healthcare$1.09B2.16$5.28 per share9.40$39.89 per share1.25SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPHAAphriaN/A-C$2.01N/AN/AN/AN/AN/AN/AN/ABHCBausch Health Cos$157M-$3.24N/A1.22N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)PBHPrestige Consumer Healthcare$190.30M$3.9112.7010.521.5717.48%11.54%6.16%8/6/2026 (Estimated)SLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest SLS, APHA, PBH, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026SLSSELLAS Life Sciences Group-$0.0450N/AN/AN/AN/AN/A8/6/2026Q1 2027PBHPrestige Consumer Healthcare$0.89N/AN/AN/A$249.68 millionN/A7/29/2026Q2 2026BHCBausch Health Cos$0.96N/AN/AN/A$2.59 billionN/A5/13/2026Q4 2026PBHPrestige Consumer Healthcare$1.39$1.23-$0.16$1.13$293.64 million$281.62 million5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPHAAphriaN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPHAAphria59.293.371.63BHCBausch Health Cos54.681.320.97PBHPrestige Consumer Healthcare0.543.572.25SLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPHAAphriaN/ABHCBausch Health Cos78.65%PBHPrestige Consumer Healthcare99.95%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipAPHAAphriaN/ABHCBausch Health Cos20.67%PBHPrestige Consumer Healthcare1.50%SLSSELLAS Life Sciences Group1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPHAAphria1,200316.80 millionN/ANot OptionableBHCBausch Health Cos20,300374.03 million296.72 millionOptionablePBHPrestige Consumer Healthcare54047.37 million46.66 millionOptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableSLS, APHA, PBH, and BHC HeadlinesRecent News About These CompaniesSellas CEO Angelos Stergiou says '100% certain' AI can be used to beat cancerJuly 24 at 12:09 PM | msn.comSLS stock rises overnight: Retail traders call new AML survival data 'huge' ahead of CEO’s Fox appearanceJuly 24 at 12:09 PM | msn.comSLS stock July rout deepens: 'Pharma Bro' Martin Shkreli questions timing of AML trial, says data may wait until ChristmasJuly 23 at 10:46 AM | msn.comSELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 6.3% - What's Next?July 22 at 11:59 AM | marketbeat.comSLS stock tracks worst month since March: Investor slashes stake by over 30% as quiet period begins ahead of AML readoutJuly 22 at 1:24 AM | msn.comSLS stock rises overnight: Retail thinks CEO just dropped buyout clues ahead of Fox appearanceJuly 21, 2026 | msn.comSELLAS Life Sciences Group (NASDAQ:SLS) & Abivax (NASDAQ:ABVX) Critical ComparisonJuly 21, 2026 | americanbankingnews.comSLS stock hits July low as AML readout nears — retail bulls see 'stellar' hint in CEO's Fox appearance next weekJuly 18, 2026 | msn.comSELLAS Life Sciences Group (SLS) Stock Looks Rich On Book Value Yet Strong On ReturnsJuly 18, 2026 | finance.yahoo.comSELLAS Life Sciences rebounds 12% as investors continue to wait for key dataJuly 18, 2026 | seekingalpha.comSELLAS Life Sciences Group (SLS) Stock Pricey Following Phase 3 Trial BuzzJuly 18, 2026 | finance.yahoo.comSellas Life (SLS) Climbs 12% Ahead of ‘Potentially Company-Defining’ Clinical Trial ResultJuly 17, 2026 | insidermonkey.comSELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 13.1% - Still a Buy?July 17, 2026 | marketbeat.comSELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 6.5% - Here's What HappenedJuly 16, 2026 | marketbeat.comSLS stock jumps overnight after new investor disclosure – retail flags ‘massive’ options bet ahead of AML dataJuly 14, 2026 | msn.comSELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught UpJuly 14, 2026 | seekingalpha.comInvestors Purchase High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)July 13, 2026 | marketbeat.comSellas Life Sciences: REGAL Trial's Delayed Events Signal Selection BiasJuly 9, 2026 | seekingalpha.comHere’s Why SELLAS (SLS) is Among the 10 Best Performing American Stocks in June 2026July 9, 2026 | finance.yahoo.comSLS stock in the spotlight as CEO pushes back on Regal trial criticism – 'Let's separate the noise from the data'July 8, 2026 | msn.comMost and least shorted mid- to mega-cap healthcare stocks at the end of JuneJuly 1, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLS, APHA, PBH, and BHC Company DescriptionsAphria TSE:APHAAphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.Bausch Health Cos NYSE:BHC$4.42 -0.03 (-0.56%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$4.42 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Prestige Consumer Healthcare NYSE:PBH$49.67 +0.73 (+1.50%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$49.69 +0.02 (+0.04%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.SELLAS Life Sciences Group NASDAQ:SLS$11.32 -1.02 (-8.27%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$11.36 +0.04 (+0.35%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
